Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Francisco Sapunar"'
Autor:
Alistair Ring, Meghan Karuturi, Emily Nash Smyth, Tasneem Lokhandwala, Kristin M. Sheffield, Joanne Willey, Orsolya Lunacsek, Francisco Sapunar, Zhanglin Lin Cui, Anna D. Coutinho, Sarah Rybowski
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 4, Pp 589-603 (2023)
Abstract Introduction Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) is the most frequently diagnosed metastatic breast cancer (mBC) subtype. Combinations of endocrine therapy (ET) with cyclin-dependent ki
Externí odkaz:
https://doaj.org/article/aa1788c9bb694e03a3c95d560933648e
Autor:
Michael Crager, Sameera R. Wijayawardana, Aaron M. Gruver, Andrea Blacklock, Christy Russell, Frederick L. Baehner, Francisco Sapunar
Publikováno v:
Breast Cancer Research, Vol 24, Iss 1, Pp 1-7 (2022)
Abstract Background The United States Food and Drug Administration recently approved a Ki-67 immunohistochemistry (IHC) assay to identify patients with early breast cancer at high disease recurrence risk. The Oncotype Dx Breast Recurrence Score® ass
Externí odkaz:
https://doaj.org/article/29436609f41c471aa39faa948b2588b3
Autor:
Alistair Ring, Meghan Karuturi, Emily Nash Smyth, Tasneem Lokhandwala, Kristin M. Sheffield, Joanne Willey, Orsolya Lunacsek, Francisco Sapunar, Zhanglin Lin Cui, Anna Coutinho, Sarah Rybowski
Publikováno v:
Advances in Therapy. 40:2515-2523
Autor:
Masakazu Toi, Frances Boyle, Young-Hyuck Im, Mattea Reinisch, David Molthrop, Zefei Jiang, Ran Wei, Francisco Sapunar, Brenda R Grimes, Sarah Cassidy Nabinger, Stephen R D Johnston
Publikováno v:
The oncologist.
The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of
Autor:
Miglena Komforti, Erinn Downs-Kelly, Francisco Sapunar, Sameera R. Wijayawardana, Aaron M. Gruver, Sunil S. Badve
Publikováno v:
Applied immunohistochemistrymolecular morphology : AIMM. 30(8)
The objective of this study was to measure concordance of results obtained from the US Food and Drug Administration-approved Ki-67 immunohistochemistry MIB-1 pharmDx assay performed on the Dako Omnis automated staining instrument (Omnis) versus resul
Publikováno v:
Anti-Cancer Drugs. 27:383-397
In the recent years, a number of targeted therapies have been approved for first-line treatment of patients with metastatic renal cell carcinoma. A systematic review was conducted to assess the clinical efficacy, safety and effect of all first-line t
Autor:
Rajendra A. Badwe, Robert Ian Nicholson, Ugochi Emeribe, Pauline Finlay, Nadia Harbeck, Francisco Sapunar, Elizabeth Anderson, Roberto Hegg, Julia Margaret Wendy Gee, José Bines, Elizabeth S. Lowe, Christian F. Singer, Irene Kuter
Publikováno v:
Breast Cancer Research and Treatment. 133:237-246
NEWEST (Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumors) is the first study to compare biological and clinical activity of fulvestrant 500 versus 250 mg in the neoadjuvant breast cancer setting. We hypothesized that fulvestrant
Autor:
Anthony Howell, Francisco Sapunar
Publikováno v:
Clinical Breast Cancer. 11:204-210
Postmenopausal women with hormone receptor-positive advanced breast cancer are candidates for endocrine therapy. As the disease will eventually progress in most patients, it is important to investigate agents with novel modes of action to reduce the
Autor:
Guy Jerusalem, Lubos Petruzelka, Miguel Martin, Jose Luiz Pedrini, Francisco Sapunar, Igor Bondarenko, Angelo Di Leo, Kelly Pendergrass, Didier Verhoeven, Sally Garnett, Roberto Torres, Mikhail Lichinitser, Iya Smirnova, Justin P.O. Lindemann, Rustem Khasanov
Publikováno v:
Journal of Clinical Oncology. 28:4594-4600
Purpose We compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per month for treatment of postmenopausal women with estrogen receptor–positive advanced breast cancer who experienced progression after prior endocrine the
Publikováno v:
Journal of Clinical Oncology. 27:4961-4965
Purpose Carpal tunnel syndrome (CTS) is a condition in which the median nerve is compressed, leading to pain and muscle weakness in the fingers and hand. Aromatase inhibitors lead to profound estrogen suppression and may be expected to increase the r